Rosuvastatin News and Research

RSS

Recaticimab injection every 1-3 months may safely lower bad cholesterol

A new PCSK9 inhibitor (recaticimab) injected every one to three months may work safely and provide more flexible dosing to lower cholesterol, according to late-breaking science presented today at the American Heart Association's Scientific Sessions 2023.

13 Nov 2023

Study compares two widely used statins for treating patients with coronary artery disease

Two widely used statins, rosuvastatin and atorvastatin, are equally effective at preventing heart attacks, strokes and death in people with coronary artery disease.

18 Oct 2023

Investigating treat-to-target low-density lipoprotein-cholesterol versus high-intensity statins for coronary artery disease

In a recent study published in JAMA, researchers investigated whether treat-to-target (TTT) low-density lipoprotein-cholesterol (LDL-C) therapy was inferior to administering statins of high intensity for clinical outcomes in the long term among coronary artery disease (CAD) patients.

8 Mar 2023

Dietary supplements taken for 'heart health' unlikely to offer meaningful impact on cholesterol levels

Six widely used dietary supplements promoted for improving heart health did not effectively lower LDL or "bad" cholesterol in comparison to a common low-dose statin medication or placebo, according to late breaking science results presented today at the American Heart Association's Scientific Sessions 2022.

7 Nov 2022

Rosuvastatin vastly superior to six common heart health supplements

Six widely used dietary supplements often advertised to promote heart health are actually ineffective at lowering cholesterol levels.

7 Nov 2022

Exploring the muscle symptoms associated with statin therapy

In a new study, investigators explored the influences of statin treatment on muscle symptoms.

31 Aug 2022

What is the optimal LDL cholesterol level for patients with cardiovascular diseases?

In a new study, the effectiveness of low low-density lipoprotein cholesterol levels in reducing the risk of atherosclerotic vascular events was explored.

6 Jul 2022

Study predicts that different statins exhibit divergent effects on host response to SARS-CoV-2 infection

A new study explores the possibility that different statins may exhibit different effects within the host and may differ in their outcomes while treating COVID-19 patients.

18 Apr 2022

Addition of alirocumab to high-intensity statin treatment reduces key measures of plaque vulnerability

Compared with a placebo, the addition of the injectable cholesterol-lowering drug alirocumab to high-intensity statin treatment in patients who have had a heart attack resulted in twofold greater reductions in three key measures of plaque vulnerability that signal risk for future cardiac events, according to research presented at the American College of Cardiology's 71st Annual Scientific Session.

3 Apr 2022

Study: Benefit-to-harm balance of statins for primary prevention of heart disease is favorable

Statins are associated with a small increased risk of side effects in patients without a history of heart disease, but these effects are mild compared with the potential benefits of treatment in preventing major cardiovascular events, say researchers in The BMJ today.

14 Jul 2021

Selective statins may reduce SARS-CoV-2 cell entry and inhibit infection

Statins are a class of drugs often used to control high cholesterol levels in obesity. Now, a study published on the preprint server medRxiv* in July 2020 suggests that statins do not aggravate the risk of COVID-19 infection and may have a small beneficial effect in some cases.

16 Jul 2020

Statin use alone or with metformin may increase survival in high-risk prostate cancer patients

Among high-risk prostate cancer patients - those with high PSA and Gleason scores of 8 or more - many will develop a difficult-to-treat disease.

10 Feb 2020

Potency and dosage of statins linked to diagnosis of osteoporosis

A team of researchers of MedUni Vienna working with the endocrinologists and gender physicians Michael Leutner and Alexandra Kautzky-Willer as well the division for complex statistical systems with Peter Klimek and Caspar Matzhold in cooperation with Complexity Science Hub Vienna were able to demonstrate for the first time a connection between the potency and dosage of statins with a diagnosis of osteoporosis, based on several million data sets.

30 Sep 2019

Higher dosage of statins can increase risk of osteoporosis, shows study

At low doses, statins could protect against bone resorption. But the higher the dosage of cholesterol-lowering drugs, the greater the probability of osteoporosis, an analysis of millions of patient data by the Complexity Science Hub Vienna shows.

30 Sep 2019

Statins are recommended far too often, study shows

Taking cholesterol-lowering drugs, or statins, as a preventive measure can reduce the risk of cardiovascular disease. A study by the University of Zurich now shows that this measure is recommended too often, as current guidelines fail to take into account the risks of side effects.

6 Dec 2018

Study examines timing of musculoskeletal adverse events that develop during statin therapy

Statins have been linked with muscle pain and other musculoskeletal adverse events in some patients. A new Pharmacology Research & Perspectives study has examined the timing of MAEs that develop during statin therapy and determined whether concomitant drugs used concurrently with statin therapy shifts the timing of MAEs.

7 Nov 2018

PCSK9 inhibitor reduces cardiovascular events in ACS patients with high cholesterol

Among patients with persistently high cholesterol despite high-intensity statin therapy, the proprotein convertase subtilisin-kexin 9 (PCSK9) inhibitor alirocumab reduced rates of major adverse cardiovascular events by 15 percent compared with placebo, in a study presented at the American College of Cardiology's 67th Annual Scientific Session.

12 Mar 2018